Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoshi Zhang

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Oncotarget|November 1, 2014
Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancerJianjun Tang, Gang Wang, Meifang Zhang, et al.
Nature Communications|June 10, 2023
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumorsDandan Li, Chao Chen, Jingjing Li, et al.
Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.
JAMA Oncology|January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical TrialXinan Sheng, Gang Huang, Meiyu Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Cell Research|February 15, 2022
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy responseJingjing He, Xinxin Xiong, Han Yang, et al.
Medcomm|January 15, 2026
Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read SequencingZhewen Wei, Yinghao Cao, Hongchao Liu, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Oncotarget|November 1, 2014
Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancerJianjun Tang, Gang Wang, Meifang Zhang, et al.
Nature Communications|June 10, 2023
A pilot study of lymphodepletion intensity for peripheral blood mononuclear cell-derived neoantigen-specific CD8 + T cell therapy in patients with advanced solid tumorsDandan Li, Chao Chen, Jingjing Li, et al.
Frontiers in Oncology|September 10, 2021
Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa TrialLili Mao, Ya Ding, Xue Bai, et al.
JAMA Oncology|January 2, 2026
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical TrialXinan Sheng, Gang Huang, Meiyu Fang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.
Journal for Immunotherapy of Cancer|October 4, 2024
Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trialBixia Tang, Yu Chen, Yu Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2024
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanomaXiaoting Wei, Zhengyun Zou, Weizhen Zhang, et al.
Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.
Cell Research|February 15, 2022
Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy responseJingjing He, Xinxin Xiong, Han Yang, et al.
Medcomm|January 15, 2026
Landscape of Somatic and Age-Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long-Read SequencingZhewen Wei, Yinghao Cao, Hongchao Liu, et al.
Pageof 9